SATB1 and hepatocellular carcinoma: In conclusion, our study not only identifies SATB1 as a potential therapeutic target to alleviate CAR-T cell exhaustion but also provides a novel strategy to enhance CAR-T cell efficacy in solid tumors, particularly HCC.